Last updated: November 6, 2026
Cefuroxime axetil is a mature, off-patent oral cephalosporin with broad generic availability and limited commercial differentiation. The originator brand, Ceftin in the United States and Zinnat in several international markets, no longer has meaningful exclusivity. Market value is concentrated in low-cost generic tablets and oral suspensions, while revenue growth is constrained by antibiotic stewardship, therapeutic substitution, and intense price competition.
Standalone global sales are not publicly disclosed because cefuroxime axetil is sold mainly through generic portfolios. The commercial trajectory is therefore best assessed through prescription volume, tender pricing, product availability, manufacturing concentration, and the performance of broader oral antibiotic portfolios rather than through originator revenue.
What is cefuroxime axetil and how is it used?
Cefuroxime axetil is the orally administered prodrug of cefuroxime, a second-generation cephalosporin. It is hydrolyzed after absorption to active cefuroxime.
| Attribute |
Data |
| Active drug |
Cefuroxime |
| Oral prodrug |
Cefuroxime axetil |
| Drug class |
Second-generation cephalosporin |
| ATC classification |
J01DC02 |
| Primary dosage forms |
Tablets and oral suspension |
| Original U.S. brand |
Ceftin |
| Major non-U.S. brand |
Zinnat |
| Common strengths |
125 mg, 250 mg, and 500 mg tablets |
| Main indications |
Respiratory, urinary tract, skin and soft-tissue, and selected sexually transmitted infections |
| Regulatory pathway |
Legacy NDA followed by ANDA generic approvals |
| Current exclusivity position |
No meaningful market exclusivity |
Cefuroxime axetil is used for susceptible bacterial infections, including acute bacterial sinusitis, acute otitis media, pharyngitis, tonsillitis, acute exacerbations of chronic bronchitis, uncomplicated skin infections, urinary tract infections, and uncomplicated gonorrhea, subject to product labeling and local treatment guidance. The FDA Ceftin label identifies dosage and indication-specific restrictions and warns against use in patients with serious beta-lactam hypersensitivity reactions [1].
The product is administered orally, generally after food to improve absorption. The suspension has different pharmacokinetic handling from tablets and is not always directly interchangeable on a milligram-for-milligram basis without reference to product labeling.
When did cefuroxime axetil lose patent and regulatory exclusivity?
Cefuroxime axetil lost practical exclusivity years ago. The product was developed and commercialized by Glaxo and related predecessor companies, with Ceftin approved in the United States in the 1980s. The original patent estate and any associated regulatory exclusivity periods have expired.
Exclusivity timeline
| Milestone |
Approximate timing |
Commercial effect |
| Cefuroxime introduced internationally |
Late 1970s to early 1980s |
Originator launch |
| U.S. Ceftin approval |
1980s |
Originator oral market established |
| Original composition and prodrug protection |
Primarily 1980s-era rights |
Later expired |
| Generic entry |
1990s and subsequent years |
Originator pricing pressure |
| Current market |
2020s |
Generic-dominated, low-margin market |
The precise patent term depended on the patent, filing date, patent-term adjustments, and jurisdiction. No live composition-of-matter or basic prodrug patent should be assumed to block generic cefuroxime axetil supply in the United States or major European markets.
The product may still be covered by manufacturing, formulation, or process patents in isolated jurisdictions, but those rights do not recreate originator-level exclusivity for the active ingredient. Generic manufacturers generally rely on expired core patents, noninfringing processes, and product-specific regulatory approvals.
What is the Orange Book status of cefuroxime axetil?
Cefuroxime axetil is an off-patent generic product in the United States. The FDA Orange Book records approved reference products and listed patents, but historical listing activity does not mean that a listed patent remains commercially blocking today [2].
Ceftin has been marketed as a reference product for cefuroxime axetil tablets and oral suspension. The FDA has also classified certain Ceftin presentations as discontinued. A discontinued designation does not, by itself, mean that the FDA withdrew the product for safety or efficacy reasons. It can reflect commercial discontinuation, replacement of an application, or other regulatory circumstances.
FDA regulatory status
| Regulatory issue |
Status |
| FDA-approved active ingredient |
Yes |
| Originator brand exclusivity |
Expired |
| Generic ANDA pathway |
Established |
| Current Paragraph IV-driven market |
No material exclusivity battle is evident from the mature market structure |
| Orange Book relevance |
Historical reference listing and any residual product-specific patents |
| Biosimilar pathway |
Not applicable |
| Controlled-substance status |
None |
Generic applicants seeking approval for cefuroxime axetil tablets or suspension generally use the ANDA pathway and must demonstrate pharmaceutical equivalence and bioequivalence to the relevant reference product. The application must also address dosage-form-specific quality requirements, including dissolution, content uniformity, stability, and suspension performance.
How many patents cover cefuroxime axetil?
The commercially important patent estate is effectively exhausted. Historical patents covered the cefuroxime molecule, the axetil prodrug, formulations, and manufacturing methods. Current generic competition is not generally determined by the number of historical patents but by whether any unexpired, enforceable patent covers a specific product, dosage form, formulation, or process in a particular jurisdiction.
What patent categories historically protected the product?
| Patent category |
Historical relevance |
Current commercial relevance |
| Cefuroxime composition patents |
Protected the antibacterial compound |
Expired |
| Cefuroxime axetil prodrug patents |
Covered oral prodrug chemistry |
Expired in major markets |
| Salt, ester, or polymorph patents |
Could support chemical stability or absorption |
Generally weak for mature products |
| Tablet formulation patents |
Covered excipient or release characteristics |
Usually expired or design-around available |
| Suspension formulation patents |
Addressed taste, stability, and dispersibility |
May affect specific products but rarely blocks market entry |
| Manufacturing patents |
Covered synthesis, crystallization, or purification |
Process-specific and often avoidable |
| Method-of-use patents |
Could cover disease-specific treatment |
Limited commercial value after broad generic entry |
The strongest remaining intellectual-property risks, if any, are likely to arise from product-specific formulation or manufacturing claims rather than from the core cefuroxime axetil molecule. Those risks must be assessed jurisdiction by jurisdiction.
Are there current Paragraph IV challenges for cefuroxime axetil?
Paragraph IV litigation is not a major current market driver for cefuroxime axetil. The product has been generic for decades, and the economic value of challenging a residual patent is limited unless a manufacturer seeks a differentiated formulation, a valuable pediatric presentation, or a market with constrained supply.
Under the Hatch-Waxman framework, an ANDA applicant can certify that a listed patent is invalid, unenforceable, or will not be infringed. A Paragraph IV certification can trigger patent litigation and, in some cases, a 30-month stay of FDA approval. That mechanism was commercially significant during the originator-to-generic transition but has limited relevance to the current mature market [3].
No material current litigation should be inferred from the historical presence of Orange Book listings. Patent status must be checked against the latest Orange Book data and active federal court dockets before an investment or launch decision.
What formulations are protected by cefuroxime axetil patents?
Tablets and oral suspensions have different technical and commercial risk profiles.
Tablets
Cefuroxime axetil tablets require control of:
- Prodrug stability and hydrolysis
- Particle size and solid-state properties
- Dissolution and bioavailability
- Excipient compatibility
- Food-effect performance
- Taste masking or coating
- Packaging and moisture protection
The tablet segment is heavily commoditized. Manufacturing scale, quality consistency, and regulatory reliability are more important than patent differentiation.
Oral suspension
The suspension has greater technical complexity. Manufacturers must manage:
- Poor aqueous solubility
- Sedimentation and redispersibility
- Palatability
- Preservative systems
- Reconstitution stability
- Dose uniformity
- Pediatric administration requirements
Suspension products can support somewhat better pricing than standard tablets when there are few approved suppliers. That advantage is usually supply-driven rather than patent-driven.
Modified-release and specialized delivery
Cefuroxime axetil is not primarily a modified-release product. Extended-release, taste-masked, combination, or device-enabled versions could theoretically create formulation barriers, but these formats have limited market penetration compared with conventional tablets and suspension.
Which companies compete in the cefuroxime axetil market?
Competition is fragmented and varies by country. Brand ownership and manufacturing rights can change through divestitures, portfolio transactions, licensing arrangements, and local registrations.
| Competitor category |
Typical participants |
Competitive basis |
| Originator portfolio |
GSK and successor commercial arrangements |
Brand recognition and legacy registrations |
| Large generic companies |
Teva, Sandoz, Lupin, and regional manufacturers |
Scale, regulatory reach, and supply |
| Contract manufacturers |
API and finished-dose suppliers in India, China, and other manufacturing hubs |
Low-cost production and private-label supply |
| Local pharmaceutical companies |
Country-specific licensees and marketers |
Hospital tenders, distribution, and local registration |
| Hospital suppliers |
Generic injectable and oral antibiotic vendors |
Contract pricing and reliable availability |
The commercial market should not be analyzed as a single global franchise. In the United States, retail generic substitution and pharmacy purchasing dominate. In Europe, national reimbursement and tender systems drive price. In emerging markets, private-sector brand generics can retain higher nominal prices but face variable quality perceptions and local competition.
How strong is the cefuroxime axetil patent estate?
The patent estate is weak from an exclusivity perspective but still relevant for freedom-to-operate analysis.
Strength assessment
| Factor |
Assessment |
| Core molecule protection |
Exhausted |
| Prodrug protection |
Exhausted in major markets |
| Formulation protection |
Limited and product-specific |
| Method-of-use protection |
Low value for broad antibiotic indications |
| Manufacturing protection |
Potentially relevant but usually design-around capable |
| Generic entry barriers |
Regulatory and supply barriers, not core patent barriers |
| Litigation leverage |
Low |
| Lifecycle-management potential |
Limited |
The main non-patent barriers are bioequivalence development, stability data, pediatric formulation quality, manufacturing validation, and reliable API sourcing. These barriers can delay entry for smaller companies but do not normally support durable premium pricing.
What is the financial trajectory for cefuroxime axetil?
Cefuroxime axetil has followed the standard trajectory of a mature small-molecule antibiotic:
- Originator-led growth after launch.
- Expansion across respiratory and urinary indications.
- Generic entry and rapid price compression.
- Portfolio migration from branded sales to generic volume.
- Continued demand from established prescribing habits and hospital or retail tenders.
- Flat or declining real pricing, with occasional revenue increases caused by shortages or supply disruption.
There is no reliable public standalone revenue series for global cefuroxime axetil sales. Public company filings generally report antibiotics within broader therapeutic or geographic categories. Ceftin-specific revenue is not normally disclosed by current manufacturers.
Financial drivers
| Driver |
Effect on revenue |
| Generic substitution |
Reduces unit price |
| Prescription volume |
Supports baseline demand |
| Antibiotic stewardship |
Limits inappropriate and routine use |
| Respiratory infection cycles |
Creates seasonal volatility |
| Hospital tenders |
Increase volume but compress margins |
| API cost inflation |
Pressures gross margin |
| Supply shortages |
Can temporarily increase realized price |
| Pediatric suspension availability |
Can improve local pricing |
| Brand loyalty |
Limited in pharmacy channels |
| Regulatory withdrawals |
Can improve remaining suppliers' volume |
A supplier with an approved suspension and dependable manufacturing can earn better returns than a tablet-only supplier. The advantage depends on actual competitor availability, reimbursement rules, and procurement contracts.
What generic launch scenarios exist for cefuroxime axetil?
Base case: stable generic supply
The most likely scenario is continued availability from multiple manufacturers, low pricing, and modest volume changes tied to infection incidence and prescribing practice.
Shortage-driven upside
A manufacturer may achieve temporary volume and pricing gains if competitors experience manufacturing failures, regulatory action, API shortages, or packaging disruptions. These gains are usually reversible.
Portfolio consolidation
Low margins may cause companies to exit the product or reduce manufacturing sites. Consolidation can improve pricing temporarily but increases supply-chain concentration.
Formulation-specific opportunity
Pediatric suspension, hard-to-source strengths, and markets with limited approved suppliers may create targeted opportunities. These are local opportunities rather than global exclusivity events.
What manufacturing and intellectual-property barriers affect supply?
Cefuroxime axetil production requires control of the ester prodrug, impurity profile, particle characteristics, and finished-product stability. The product is more technically demanding than a simple, highly soluble tablet.
Manufacturing risks include:
- Dependence on a limited number of qualified API suppliers
- Variability in particle size and solid-state form
- Hydrolytic degradation
- Failed dissolution or bioequivalence studies
- Suspension sedimentation and dose-uniformity problems
- Packaging failures caused by moisture sensitivity
- Regulatory observations at API or finished-dose sites
- Country-specific registration maintenance costs
These issues can create temporary supply advantages, but they are not equivalent to durable patent protection.
What patent litigation and licensing deals affect cefuroxime axetil?
No current high-value patent litigation or licensing arrangement defines the global cefuroxime axetil market. Historical commercialization involved originator rights and regional distribution arrangements associated with Glaxo and predecessor companies. Current generic supply is generally based on independent regulatory approvals, local marketing authorizations, contract manufacturing, and portfolio acquisitions.
Any transaction involving cefuroxime axetil is more likely to concern a broader generic portfolio than the molecule alone. The asset value of a standalone cefuroxime axetil license is limited unless it includes a differentiated formulation, a protected market, a scarce registration, or a reliable hospital tender position.
How does cefuroxime axetil compare with competing antibiotics?
| Product |
Class |
Market position |
Competitive relationship |
| Cefuroxime axetil |
Oral second-generation cephalosporin |
Mature generic |
Competes in respiratory and urinary infections |
| Amoxicillin/clavulanate |
Penicillin combination |
Broad primary-care use |
Major substitute for respiratory and sinus infections |
| Cefdinir |
Oral third-generation cephalosporin |
Generic, often higher-cost in some markets |
Substitutes in outpatient infections |
| Cefpodoxime |
Oral third-generation cephalosporin |
Generic |
Competes in respiratory and urinary indications |
| Azithromycin |
Macrolide |
Mature generic |
Alternative where beta-lactams are unsuitable |
| Levofloxacin |
Fluoroquinolone |
Generic, stewardship-constrained |
Alternative for selected infections |
| Oral cefalexin |
First-generation cephalosporin |
Low-cost generic |
Competes in skin and urinary infections |
Cefuroxime axetil’s clinical and commercial position is strongest where prescribers value cephalosporin activity and oral dosing but seek an alternative to amoxicillin-based therapy. Its position is weaker where low price, narrow-spectrum prescribing, or local resistance guidance favors other agents.
What are the key risks for investors and generic manufacturers?
The primary risks are commercial rather than patent-based:
- Persistent price erosion
- Restricted antibiotic prescribing
- Substitution by amoxicillin/clavulanate and newer generics
- Low reimbursement ceilings
- API and excipient shortages
- Regulatory action against manufacturing sites
- Product discontinuation caused by low margins
- Limited ability to differentiate a conventional tablet
- Country-specific tender losses
- Reputational or supply risks associated with contract manufacturers
Potential upside is concentrated in supply reliability, pediatric formulations, underserved markets, and distributors with strong institutional purchasing access.
Key Takeaways
- Cefuroxime axetil is a mature, off-patent oral cephalosporin.
- Ceftin and Zinnat no longer provide meaningful originator exclusivity.
- The core molecule and prodrug patent positions have expired in major markets.
- Current commercial barriers are manufacturing, quality, registration, and supply-chain related.
- No biosimilar pathway applies because cefuroxime axetil is a small-molecule drug.
- Paragraph IV litigation is not a major current market driver.
- Tablets are highly commoditized; oral suspension can command better economics where supply is limited.
- Standalone global revenue is not publicly disclosed in a reliable, comparable format.
- Financial performance depends on generic volume, tender access, product availability, and temporary shortages.
- The strongest investment thesis is operational execution, not patent exclusivity.
FAQs
Is cefuroxime axetil still under patent?
No. The commercially important core and prodrug patent rights have expired in major markets. Product-specific formulation or process patents must be assessed separately by jurisdiction.
Is Ceftin still commercially protected?
No meaningful market exclusivity remains for Ceftin. Generic substitution has been established for many years.
Can a company obtain orphan-drug exclusivity for cefuroxime axetil?
Not for the conventional broad indications associated with the product. Orphan designation would require a qualifying rare disease and would not revive expired composition patents.
Does cefuroxime axetil have biosimilar competition?
No. Biosimilars apply to biological products. Cefuroxime axetil is a conventional small-molecule drug and competes through generic ANDA or equivalent national pathways.
Is cefuroxime axetil a good licensing asset?
Usually only as part of a broader generic portfolio. Standalone licensing value is limited unless the deal includes a differentiated suspension, scarce regulatory approvals, protected geographic rights, reliable supply capacity, or institutional contracts.
References
-
U.S. Food and Drug Administration. (2016). Ceftin (cefuroxime axetil) tablets and oral suspension prescribing information. FDA.
-
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.
-
U.S. Food and Drug Administration. (2015). Guidance for industry: 180-day exclusivity when multiple ANDA applicants qualify for Paragraph IV certification. FDA.
-
World Health Organization Collaborating Centre for Drug Statistics Methodology. (2024). ATC/DDD index: J01DC02 cefuroxime. WHO.
-
U.S. Food and Drug Administration. (2024). Drugs@FDA: FDA-approved drugs database. FDA.
